Skip to main content
Premium Trial:

Request an Annual Quote

Mental Health PGx Firm Assurex Health Nabs $30M Financing

NEW YORK (GenomeWeb) – Assurex Health today announced it has raised $30 million to support the clinical adoption and development of the firm's GeneSight neuropsychiatric pharmacogenomic products. 

Participants in the financing included new investors American Financial Group and Cross Creek Advisors, as well as existing investors Cincinnati Children's Hospital Medical Center, Sequoia Capital, Claremont Creek Ventures, Mayo Clinic, CincyTech, Allos Ventures, and Danmar Capital.

In May, Assurex said that it attracted $7 million in investments. Today's $30 million figure is in addition to the May financing and brings the total equity investment in the firm to $60 million, a spokesman for the company told Genomeweb.

The GeneSight technology is based on combinatorial pharmacogenomics, and Assurex said that more than 9,000 clinicians have used GeneSight products in making treatment decisions for more than 125,000 patients. The Mason, Ohio-based firm also noted that the US Department of Veterans Affairs and Medicare recently added GeneSight's multi-gene psychotropic test to their coverage plans.


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.